WEBVTT

1
00:00:00.284 --> 00:00:04.298
Elena has had a myocardial infarction
and has type two diabetes.

2
00:00:04.457 --> 00:00:06.953
She is prescribed a high-intensity statin,

3
00:00:07.017 --> 00:00:10.718
but a prescription does not
establish actual use or tolerance.

4
00:00:10.848 --> 00:00:14.573
Review the medicine, access,
missed doses and current

5
00:00:14.593 --> 00:00:17.232
lipid response before
choosing the next treatment.

6
00:00:17.390 --> 00:00:20.669
Do not assume statin intolerance
from the information given.

7
00:00:20.946 --> 00:00:23.954
Use CLEAR Outcomes to
practice reading an endpoint.

8
00:00:24.150 --> 00:00:28.064
It enrolled thirteen thousand nine
hundred seventy statin-intolerant

9
00:00:28.084 --> 00:00:32.614
patients with, or at high risk
for, cardiovascular disease.

10
00:00:32.862 --> 00:00:36.189
The primary composite event occurred
in eleven point seven percent

11
00:00:36.418 --> 00:00:41.160
with bempedoic acid and thirteen
point three percent with placebo.

12
00:00:41.382 --> 00:00:44.207
The absolute difference was
one point six percentage

13
00:00:44.227 --> 00:00:47.742
points over a median follow-up
of forty point six months.

14
00:00:47.972 --> 00:00:52.128
That is a trial result, not Elena's
predicted personal benefit.

15
00:00:52.286 --> 00:00:54.957
Benefit and safety belong
in the same discussion.

16
00:00:55.148 --> 00:00:57.119
Gout and gallstones were more frequent

17
00:00:57.139 --> 00:00:59.470
with bempedoic acid in CLEAR Outcomes.

18
00:00:59.651 --> 00:01:02.101
Review the current label, relevant history,

19
00:01:02.259 --> 00:01:05.862
interactions, other treatment
options and access.

20
00:01:06.226 --> 00:01:10.093
The trial's population matters:
Elena should not be assigned to a

21
00:01:10.113 --> 00:01:14.624
statin-intolerant treatment pathway
without first confirming her experience.

22
00:01:14.807 --> 00:01:17.314
Apply the same discipline to new therapies.

23
00:01:17.484 --> 00:01:21.783
A lower biomarker does not by
itself prove fewer clinical events.

24
00:01:21.989 --> 00:01:25.951
Identify the population,
comparator, clinical endpoint,

25
00:01:25.971 --> 00:01:30.468
absolute result and uncertainty,
then check regulatory status.

26
00:01:30.636 --> 00:01:33.582
Investigational treatment
is not established care.

27
00:01:33.669 --> 00:01:36.711
For Elena's handoff, justify
the next secondary-prevention

28
00:01:36.751 --> 00:01:39.403
decision and name who
will check the response.